Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock
by Zacks Equity Research
Allogene Therapeutics (ALLO) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.
Will Allogene Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.